 Lauren Fishbein
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pheochromocytoma | 27 | 2025 | 55 | 11.820 |
Why?
| | Paraganglioma | 25 | 2025 | 49 | 10.740 |
Why?
| | Adrenal Gland Neoplasms | 26 | 2025 | 81 | 10.370 |
Why?
| | Neuroendocrine Tumors | 5 | 2024 | 99 | 2.420 |
Why?
| | Succinate Dehydrogenase | 7 | 2025 | 46 | 1.260 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1159 | 1.010 |
Why?
| | Mutation | 12 | 2025 | 3702 | 0.920 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 33 | 0.870 |
Why?
| | Genetic Predisposition to Disease | 6 | 2021 | 2271 | 0.750 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 55 | 0.730 |
Why?
| | Trans-Activators | 2 | 2021 | 392 | 0.710 |
Why?
| | Meningioma | 1 | 2022 | 82 | 0.700 |
Why?
| | Hospice Care | 1 | 2023 | 194 | 0.670 |
Why?
| | Head and Neck Neoplasms | 4 | 2022 | 544 | 0.640 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 200 | 0.630 |
Why?
| | Adrenocortical Carcinoma | 4 | 2022 | 63 | 0.620 |
Why?
| | Paraganglioma, Extra-Adrenal | 2 | 2022 | 7 | 0.610 |
Why?
| | Chromaffin Cells | 1 | 2018 | 3 | 0.590 |
Why?
| | Genetic Testing | 6 | 2021 | 422 | 0.570 |
Why?
| | Hypertension | 3 | 2022 | 1235 | 0.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2024 | 1327 | 0.510 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 609 | 0.500 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2022 | 60 | 0.490 |
Why?
| | Genome, Human | 1 | 2018 | 393 | 0.490 |
Why?
| | Disease Management | 2 | 2023 | 591 | 0.470 |
Why?
| | Germ-Line Mutation | 5 | 2021 | 140 | 0.430 |
Why?
| | Humans | 43 | 2025 | 129527 | 0.430 |
Why?
| | Exome | 1 | 2015 | 216 | 0.430 |
Why?
| | Nuclear Proteins | 2 | 2017 | 659 | 0.430 |
Why?
| | DNA Helicases | 1 | 2015 | 146 | 0.420 |
Why?
| | Mutation Rate | 1 | 2013 | 25 | 0.410 |
Why?
| | Genetic Heterogeneity | 1 | 2012 | 58 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1559 | 0.370 |
Why?
| | Catecholamines | 3 | 2022 | 95 | 0.350 |
Why?
| | Membrane Proteins | 3 | 2021 | 1118 | 0.310 |
Why?
| | Neurofibromatosis 1 | 3 | 2019 | 50 | 0.290 |
Why?
| | Middle Aged | 14 | 2025 | 31087 | 0.270 |
Why?
| | Societies, Medical | 3 | 2021 | 757 | 0.260 |
Why?
| | von Hippel-Lindau Disease | 2 | 2019 | 12 | 0.260 |
Why?
| | Adult | 12 | 2025 | 35505 | 0.250 |
Why?
| | Syndrome | 2 | 2019 | 338 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2017 | 30 | 0.240 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2024 | 11 | 0.220 |
Why?
| | Drug Therapy | 2 | 2015 | 80 | 0.220 |
Why?
| | Cohort Studies | 5 | 2021 | 5423 | 0.210 |
Why?
| | Aged | 8 | 2025 | 22063 | 0.210 |
Why?
| | Neoplasms | 1 | 2018 | 2450 | 0.210 |
Why?
| | Male | 14 | 2025 | 63586 | 0.200 |
Why?
| | Cadherins | 1 | 2024 | 187 | 0.200 |
Why?
| | Retrospective Studies | 8 | 2024 | 14532 | 0.200 |
Why?
| | Neoplasm Grading | 2 | 2020 | 283 | 0.200 |
Why?
| | Cost of Illness | 1 | 2024 | 276 | 0.190 |
Why?
| | Dioxygenases | 1 | 2022 | 27 | 0.190 |
Why?
| | Young Adult | 6 | 2024 | 12438 | 0.190 |
Why?
| | X-linked Nuclear Protein | 2 | 2025 | 8 | 0.180 |
Why?
| | Female | 15 | 2025 | 68650 | 0.180 |
Why?
| | Pennsylvania | 1 | 2020 | 108 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 374 | 0.170 |
Why?
| | Otolaryngologists | 1 | 2020 | 11 | 0.170 |
Why?
| | Prognosis | 5 | 2022 | 3772 | 0.170 |
Why?
| | North America | 1 | 2021 | 294 | 0.170 |
Why?
| | Cyclophosphamide | 2 | 2017 | 234 | 0.160 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2022 | 225 | 0.160 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2019 | 8 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 169 | 0.160 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 931 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1510 | 0.160 |
Why?
| | Transcriptome | 2 | 2024 | 875 | 0.150 |
Why?
| | Neurofibromin 1 | 2 | 2013 | 25 | 0.150 |
Why?
| | Medical Oncology | 1 | 2021 | 267 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 27 | 0.140 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2018 | 35 | 0.140 |
Why?
| | Adolescent | 5 | 2024 | 20409 | 0.140 |
Why?
| | Cell Proliferation | 3 | 2021 | 2367 | 0.140 |
Why?
| | Electron Transport Complex II | 1 | 2017 | 25 | 0.140 |
Why?
| | Survival Analysis | 1 | 2020 | 1270 | 0.140 |
Why?
| | Pol1 Transcription Initiation Complex Proteins | 1 | 2017 | 5 | 0.140 |
Why?
| | Body Weight | 1 | 2021 | 941 | 0.140 |
Why?
| | Dacarbazine | 1 | 2017 | 93 | 0.140 |
Why?
| | Gene Fusion | 1 | 2017 | 25 | 0.130 |
Why?
| | Vincristine | 1 | 2017 | 108 | 0.130 |
Why?
| | Palliative Care | 1 | 2023 | 704 | 0.130 |
Why?
| | Endocrinologists | 1 | 2016 | 12 | 0.130 |
Why?
| | Creatine | 1 | 2016 | 58 | 0.130 |
Why?
| | Homologous Recombination | 1 | 2016 | 23 | 0.130 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 35 | 0.130 |
Why?
| | Apoptosis | 3 | 2021 | 2488 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4891 | 0.120 |
Why?
| | alpha-Methyltyrosine | 1 | 2015 | 2 | 0.120 |
Why?
| | Mitochondrial Diseases | 1 | 2016 | 90 | 0.120 |
Why?
| | Oxidative Phosphorylation | 1 | 2016 | 187 | 0.120 |
Why?
| | Adrenalectomy | 1 | 2015 | 66 | 0.120 |
Why?
| | Endocrinology | 1 | 2016 | 73 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 647 | 0.120 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 1997 | 0.120 |
Why?
| | Paclitaxel | 1 | 2016 | 217 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 486 | 0.120 |
Why?
| | Telomere Homeostasis | 1 | 2015 | 29 | 0.120 |
Why?
| | Radiotherapy | 1 | 2015 | 185 | 0.120 |
Why?
| | Tumor Burden | 1 | 2015 | 287 | 0.110 |
Why?
| | Research Design | 1 | 2020 | 1043 | 0.110 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2015 | 99 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 388 | 0.100 |
Why?
| | 3-Iodobenzylguanidine | 1 | 2013 | 7 | 0.100 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 15 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 825 | 0.100 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 19 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 988 | 0.100 |
Why?
| | Abdominal Neoplasms | 1 | 2013 | 34 | 0.100 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 35 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 936 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 875 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 391 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5078 | 0.100 |
Why?
| | Telomere | 1 | 2015 | 232 | 0.100 |
Why?
| | Multiple Endocrine Neoplasia | 1 | 2012 | 4 | 0.100 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5429 | 0.090 |
Why?
| | Quality of Life | 1 | 2023 | 2694 | 0.090 |
Why?
| | Mass Screening | 1 | 2019 | 1186 | 0.090 |
Why?
| | Prospective Studies | 1 | 2023 | 7150 | 0.090 |
Why?
| | Chromatin | 1 | 2015 | 478 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 482 | 0.090 |
Why?
| | Models, Biological | 1 | 2018 | 1717 | 0.090 |
Why?
| | Schwann Cells | 1 | 2010 | 32 | 0.090 |
Why?
| | Comprehension | 1 | 2012 | 165 | 0.080 |
Why?
| | Child | 5 | 2022 | 20932 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1461 | 0.080 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 431 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 2 | 2025 | 311 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1438 | 0.080 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7052 | 0.080 |
Why?
| | Progesterone | 1 | 2010 | 244 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1642 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1281 | 0.080 |
Why?
| | Estrogens | 1 | 2010 | 346 | 0.070 |
Why?
| | Signal Transduction | 1 | 2021 | 4916 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2010 | 804 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2013 | 732 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1684 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1636 | 0.070 |
Why?
| | Blood Pressure | 1 | 2013 | 1735 | 0.060 |
Why?
| | DNA Modification Methylases | 1 | 2025 | 13 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2044 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2025 | 20 | 0.060 |
Why?
| | Risk Factors | 2 | 2021 | 9779 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 3181 | 0.060 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2025 | 235 | 0.050 |
Why?
| | Telomerase | 1 | 2025 | 230 | 0.050 |
Why?
| | Pituitary Neoplasms | 1 | 2024 | 177 | 0.050 |
Why?
| | Succinates | 1 | 2022 | 23 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 115 | 0.050 |
Why?
| | Succinic Acid | 1 | 2022 | 39 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 87 | 0.050 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 26 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 282 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2002 | 315 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2022 | 176 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 211 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 326 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 318 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2021 | 227 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 357 | 0.040 |
Why?
| | DNA Methylation | 1 | 2023 | 606 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 7 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 8 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 627 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 16 | 0.040 |
Why?
| | Histones | 1 | 2023 | 589 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 35 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 47 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3392 | 0.040 |
Why?
| | Immunoblotting | 1 | 2018 | 303 | 0.040 |
Why?
| | Animals | 3 | 2022 | 35334 | 0.040 |
Why?
| | Oncogenes | 1 | 2018 | 110 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 328 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 622 | 0.030 |
Why?
| | Phosphocreatine | 1 | 2016 | 43 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 500 | 0.030 |
Why?
| | Platinum Compounds | 1 | 2016 | 10 | 0.030 |
Why?
| | Genomics | 1 | 2021 | 715 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 167 | 0.030 |
Why?
| | Mitochondria, Muscle | 1 | 2016 | 111 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 376 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 632 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 583 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 850 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1684 | 0.030 |
Why?
| | United States | 2 | 2021 | 13865 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 591 | 0.030 |
Why?
| | Exercise Test | 1 | 2016 | 608 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1211 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 776 | 0.030 |
Why?
| | Preoperative Care | 1 | 2015 | 337 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 502 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1714 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3058 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1614 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1094 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 108 | 0.020 |
Why?
| | Mice | 2 | 2022 | 16973 | 0.020 |
Why?
| | Drug Implants | 1 | 2010 | 82 | 0.020 |
Why?
| | Ovariectomy | 1 | 2010 | 137 | 0.020 |
Why?
| | Mice, SCID | 1 | 2010 | 350 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2875 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2010 | 2887 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 10232 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 378 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 482 | 0.010 |
Why?
| | Exons | 1 | 2002 | 340 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5468 | 0.010 |
Why?
| | Infant | 1 | 2010 | 9005 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 10499 | 0.010 |
Why?
|
|
Fishbein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|